Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 January 2023 | Story Leonie Bolleurs | Photo Leonie Bolleurs
UFS unveiled new spectrograph
Assisting Prof Richard Gray with the installation of the spectrograph and the polarimeter were the Electronics and Instrumentation departments at both the UFS and the ASU. Left from the spectrograph, are from the left, front: Innes Basson, Head of the Department of Electronics and Instrumentation, Prof Pieter Meintjes, Senior Professor in the Department of Physics, Mark Jackson, Department of Electronics and Instrumentation, Hélène Szegedi, Lecturer in the Department of Physics, and Prof Richard Gray. At the right, from the spectrograph, front, are Natali Matchelt, master’s student, Izak van der Westhuizen, Lecturer in the Department of Physics; Barend Crous, Department of Electronics and Instrumentation; middle: Wian Smit, master’s student, Joleen Barnard, master’s student; back: Kobus Krüger, Department of Electronics and Instrumentation, Henri Roodt, Department of Electronics and Instrumentation; and Dr Hendrik van Heerden, Department of Physics.

The University of the Free State (UFS) is gearing up to be a leading academic institution in astronomical research. The institution successfully mounted a spectrograph with a polarimeter to the Boyden Observatory 1,5-m telescope that will provide scientists with visual access to both the Northern and Southern Hemispheres. 

The instrument, which can be accessed from Boyden, an astronomical research observatory and science education centre a few kilometres outside Bloemfontein, will allow researchers such as the Astrophysics Group at the UFS to do simultaneous polarimetry and spectroscopy of astronomical sources. This is vital for the research they are working on.

Mounting the spectrograph to the telescope and installing the polarimeter completed the upgrade of the 1,5-m telescope and is a leap forward for the astrophysics group at the UFS. The upgraded telescope with the spectropolarimeter, with a valued cost of R1.5 million, will also provide unique opportunities for collaborative research between the Astrophysics Groups at the UFS and researchers from the Appalachian State University (ASU). This adds greatly to the astrophysics research capacity at the university.
 
Prof Richard Gray, who 2019 started with the development of the astronomical spectrograph for the UFS Department of Physics, is a world-renowned expert in stellar spectroscopy, from the Department of Physics and Astronomy at ASU in North Carolina in the US. He was mainly responsible for the development and building of the instrument. 

Prof Pieter Meintjes, Senior Professor from the UFS Department of Physics, describes the moment that installation was completed as a feeling of enormous relief. “It took many hours of hard work, planning and testing to marry the 90-year 1,5-m telescope with the new sophisticated instrument,” he says. 

Adding value to graduate programme

Besides the development and installation of the spectrograph, Prof Gray also designed and built a polarimeter which can be integrated with the spectrograph. When placed inside the spectrograph, this piece of equipment transforms the spectrograph into a spectropolarimeter, giving it additional functionality. “This allows us, for example, to detect and analyse polarised light. It enables us to study the effect of magnetic fields in astronomical sources which introduce various polarisation signatures that can be detected with the polarimeter,” explains Prof Gray.

“I am fascinated by the polarimetric capabilities that we never had before. It is a great step forward,” remarks Prof Meintjes. 

“The Department of Electronics and Instrumentation at the UFS played an enormous role in the building of several components of the instrument that Prof Gray designed, as well as getting the 1.5-m telescope research ready so that the completed instrument could be mounted to the telescope”, says Prof Meintjes

He envisages that the research instrument will be ready for research purposes by March this year. Up till then researchers, graduates, and third-year students will have the opportunity to spend time on the spectrograph to familiarise themselves with it.

polarimeter
Prof Richard Gray posing with the polarimeter. With him is Prof Pieter Meintjes. (Photo: Leonie Bolleurs)


“Once installation is finalised, the UFS will be the only academic institution in South Africa with access to a 1.5-m telescope paired with a spectrograph. This gives us an edge in terms of our astrophysics programme and the training we provide our students. It also adds so much value to our graduate programme,” he says.

New instrument provides much flexibility

The spectrograph offers Prof Meintjes many possibilities for his research, and he is eager to put the instrument to use. To study binary systems as well as the jets of Active Galactic Nuclei (AGN), you need a spectrograph, preferably with polarimetric capabilities. It can also be applied to finding elements at the surface levels of stars so that their chemical composition can be determined.

“In the past, we needed to send our researchers to Sutherland and they were never guaranteed clear skies. Having this facility gives us so much flexibility,” he says.

 

Tsebo Matsoso and Siphephelo Ndlovu

Prof Brian van Soelen from the Department of Physics will be a key user of the spectrograph for his research. He is also playing an important role in terms of postgraduate training and research where the spectrograph is applied. 

Photo: Mart-Mari Duvenhage

  

 


The polarimeter converts the spectrograph to a spectropolarimeter. This instrument, which is mounted on a telescope (in the case of the UFS, it is mounted on the Boyden 1,5-m telescope) enables the user to detect whether radiation from  astronomical objects are polarised and to analyse the level of polarisation of the  light. Scientists can then, for instance, study the effect of magnetic fields in astronomical sources, which introduce various polarisation signatures (typically with a characteristic  level of polarisation).

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept